Experimental efficacy of a trivalent vaccine containing porcine circovirus types 2a/b (PCV2a/b) and Mycoplasma hyopneumoniae against PCV2d and M. hyopneumoniae challenges

• Published in: Veterinary microbiology 2021-07, Vol.258, p.109100-109100, Article 109100
• Main Authors: Yang, Siyeon, Oh, Taehwan, Park, Kee Hwan, Cho, Hyejean, Suh, Jeongmin, Chae, Chanhee
• Format: Article
• Language: English
• Subjects: Age; Dosage; Enzootic pneumonia; Lungs; Mycoplasma hyopneumoniae; Porcine circovirus type 2; Porcine respiratory disease complex; Trachea; Vaccination; Vaccines; Viremia; γ-Interferon
• ISSN: 0378-1135; 1873-2542
• DOI: 10.1016/j.vetmic.2021.109100

•A trivalent vaccine reduced the amount of PCV2d load in blood and M. hyopneumoniae load in larynx.•A trivalent vaccine reduced the severity of lung and lymphoid lesions.•A trivalent vaccine protected pigs against either PCV2d or M. hyopneumoniae challenge or both. The purpose of this experimental study was to evaluate the efficacy of a new trivalent vaccine containing porcine circovirus types 2a/b (PCV2a/b) and Mycoplasma hyopneumoniae. Pigs were administered the vaccine intramuscularly as either at 3 and 24 days of age with 1.0 mL or at 21 days of age with 2.0 mL according to the manufacturer’s recommendations. The pigs were challenged at 42 days of age with either PCV2d (intranasal route) or M. hyopneumoniae (intratracheal route), or both. No statistical differences were observed between the one-dose and two-dose experiments based on clinical (growth performance), immunological (protective immunity), microbiological (viremia and laryngeal swab), and pathological (pulmonary and lymphoid lesion) outcomes. Pigs in vaccinated/challenged and unvaccinated/unchallenged groups showed significant difference in growth performance compared to pigs in the unvaccinated/challenged group in both dosage experiments. Vaccinated pigs elicited a significant amount of protective immunity for PCV2d-specific neutralizing antibodies and interferon-γ secreting cells (IFN-γ-SC) as well as M. hyopneumoniae-specific IFN-γ-SC significantly post-challenge compared to unvaccinated/challenged pigs. Vaccination and challenge reduced the viral load amount of PCV2d in the blood and reduced the M. hyopneumoniae load in laryngeal swab, while simultaneously reducing both pulmonary and lymphoid lesion severity when compared to unvaccinated/challenged pigs. Trivalent vaccination provided good protection against a single PCV2d challenge, single M. hyopneumoniae challenge, and a PCV2d/M. hyopneumoniae dual challenge.